Banner
Late-Breaking Analysis In Hypertension Shows That Antihypertensive Treatments Differ In Their Ability To Preserve Lives

STOCKHOLM, August 30, 2010 /PRNewswire/ -- According to the results of a late-breaking analysis...

Clinical Results For New Treatment Of Bacterial Vaginosis Infection

The Swedish company Laccure AB recently got CE marking as a Class IIa medical device product for...

88 Percent Of UK Doctors Believe Whiplash Claims Are Exaggerated

AXA, a UK car insurer, has surveyed UK doctors as part of its ongoing campaign to understand the...

On Facebook, Women Are More Plentiful But Men Are Better Ad Targets

Global digital marketing companies Resolution Media and Kenshoo Social published a new report today...

User picture.
Anna OhldenRSS Feed of this column.

Media Relations Executive, PR Newswire Europe... Read More »

 Blogroll
The Sports Network Continues To Expand Its Global Reach With Mobile Services And Contec Alliance

The Sports Network Continues To Expand Its Global Reach With Mobile Services And Contec Alliance

Sep 09 2008 | comment(s)

HATBORO, Pennsylvania, September 9 /PRNewswire/ --

Interoperability Agreement Extends Network For SEPA Payments

Interoperability Agreement Extends Network For SEPA Payments

Sep 09 2008 | comment(s)

UTRECHT, Netherlands and LONDON, September 9 /PRNewswire/ -- VocaLink and Equens, have implemented a bilateral link for the exchange of SEPA payments. This is a major step in the implementation of the EACHA(1) framework announced in October 2007 to help establish interoperability between banks and European CSMs(2). The arrangement supports both companies' SEPA offering while helping to create a more competitive market by allowing banks to choose the payments processor or processors that best meet their needs.

Fenofibrate Reduces The Risk Of Amputations In Patients With Type 2 Diabetes

Fenofibrate Reduces The Risk Of Amputations In Patients With Type 2 Diabetes

Sep 09 2008 | comment(s)

ROME, September 9 /PRNewswire/ --

- Exciting New Data From the FIELD Study Show Additional Microvascular-Associated Benefits of Fenofibrate

- The First Time in a Large-Scale Prospective Study That any Lipid-Modifying Therapy has Been Shown to Significantly Reduce the Risk of Lower-Limb Amputation in Patients With Type 2 Diabetes

BioCis Pharma Receives 1.6 Million EURO New Financing To Speed The Clinical Phase I/II Programme Of The Company's Dermatology Pr

BioCis Pharma Receives 1.6 Million EURO New Financing To Speed The Clinical Phase I/II Programme Of The Company's Dermatology Pr

Sep 09 2008 | comment(s)

TURKU, Finland, September 9 /PRNewswire/ -- BioCis Pharma Ltd announced that it has received almost 1.6 million EURO new R&D financing. The money is specifically targeted for the clinical testing of the company's dermatology products.

"The new financing will further speed up the clinical phase I/II programme of our topical emulsion cream product. It is our intention to carry out up to four separate clinical studies in healthy volunteers and patients with inflammatory skin conditions, such as atopic dermatitis" says Lasse Leino, CEO of BioCis Pharma.

Learn Today. Design Tomorrow. ESC India, Your Gateway To India's Leading Technology And Solutions Providers For The Growing Embe

Learn Today. Design Tomorrow. ESC India, Your Gateway To India's Leading Technology And Solutions Providers For The Growing Embe

Sep 09 2008 | comment(s)

MUMBAI, India, September 9 /PRNewswire/ --

Nucletron Announces Advances In Image-Guided Adaptive Brachytherapy Technology For Gynecologic Cancers Through Partnership With

Nucletron Announces Advances In Image-Guided Adaptive Brachytherapy Technology For Gynecologic Cancers Through Partnership With

Sep 09 2008 | comment(s)

VEENENDAAL, Netherlands, September 9 /PRNewswire/ --

- Oncentra(R) GYN to Officially Launch at ESTRO 2008 in Sweden, September 14-18 and ASTRO 2008 in Boston, September 21-25